Physician profile
Heidi D Larison
NPI 1447455662
$6,125.54
in general payments reported to CMS, 2019-2025
48 companies · $895 in 2025
The $895 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $449 · 2020: $846 · 2021: $1,331 · 2022: $1,055 · 2023: $803 · 2024: $746 · 2025: $895.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,445.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,445.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,022.50 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $909.15 | 2021-2025 | |
| Lilly USA, LLC | $799.14 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $477.28 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $344.69 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $213.15 | 2019-2023 | |
| Amarin Pharma, INC. | $186.27 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $180.82 | 2019-2025 | Spravato, Xarelto, Invega Sustenna |
| Abbott Laboratories | $150.01 | 2021-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $132.02 | 2019-2023 | Veozah, Myrbetriq |
| Pfizer INC. | $129.64 | 2019-2025 | |
| Esperion Therapeutics, INC. | $121.78 | 2020-2025 | Nexletol |
| Amgen INC. | $120.47 | 2019-2025 | Evenity, Prolia, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $104.97 | 2022-2025 | |
| Supernus Pharmaceuticals, INC. | $99.64 | 2019-2024 | Qelbree |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heidi Larison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.